Skip to content
Educational calculator · Updated 2026

Semaglutide Dose Converter

Wegovy®, Ozempic® and post-patent generics: equivalence between desired dose (mg), injected volume (mL) and clicks on the pen.

Educational aid. Does not prescribe, does not replace individualized medical assessment.

1. Select the presentation

Wegovy® · Ozempic® · regional generics

2. Desired dose (mg)

Move either slider — both stay in sync in real time.

1.00mg
22clicks
0.051.00 mg
0 – 22

The two sliders are synced. You can also type the exact number of clicks below.

/ 22
How the calculation works
clicks ≈ ( dose mg ÷ concentration mg/mL ) × 30

Approximation reported in the label. Each pen delivers approximately 30 clicks per injected mL.

Approximate equivalence · Ozempic 1 mg → Wegovy

When a patient already in follow-up switches between pen strengths, the number of clicks changes — because the concentration changes. Approximate equivalences, based on the 30 clicks/mL rule.

Ozempic 1 mg (clicks)Wegovy 1.7 mg (clicks)Wegovy 2.4 mg (clicks)
1064
20118
301813
402417
503021
603625
704229

Commercial names recognized internationally

Semaglutide is the active ingredient (INN). It is marketed worldwide under different brand names:

Originator brands · Novo Nordisk
Wegovy®INJECTABLE
Injectable SC · weekly

approved for chronic weight management

Ozempic®INJECTABLE
Injectable SC · weekly

approved for type 2 diabetes

Rybelsus®ORAL
Oral · daily tablet

not injectable; the only oral form of semaglutide.

Brazilian post-patent generics (illustrative example)

After the expiration of the semaglutide patent in Brazil (March 2026), the national regulator (ANVISA) approved generic registrations of the molecule. Below are the first two — they illustrate a global trend: as exclusivity ends in each jurisdiction, regional generics tend to emerge under local trade names.

Poviztra®
EMS · Brazil
Extensior®
Eurofarma · Brazil
Patent and access

Semaglutide patent expiration timelines vary by jurisdiction. As exclusivity ends, generic versions tend to expand access and substantially lower the cost of the molecule, with a direct impact on long-term adherence.

No conflict of interest

The commercial names cited above are mentioned purely for educational recognition of the active ingredient (semaglutide). Peptide Academy has no financial, commercial or contractual relationship with Novo Nordisk or any other manufacturer. Registered trademarks belong to their respective owners.

⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.